TD-19, an erlotinib derivative, induces epidermal growth factor receptor wild-type nonsmall-cell lung cancer apoptosis through CIP2A-mediated pathway
TT Chao, CY Wang, CC Lai, YL Chen, YT Tsai… - … of Pharmacology and …, 2014 - ASPET
Some patients with nonsmall-cell lung cancer (NSCLC) without epidermal growth factor
receptor (EGFR) mutations still respond to gefitinib and erlotinib, suggesting that there may …
receptor (EGFR) mutations still respond to gefitinib and erlotinib, suggesting that there may …
[PDF][PDF] TD-19, an Erlotinib Derivative, Induces Epidermal Growth Factor Receptor Wild-Type Nonsmall-Cell Lung Cancer Apoptosis through CIP2A-Mediated Pathway …
TT Chao, CY Wang, CC Lai, YL Chen… - THE JOURNAL OF …, 2014 - academia.edu
Some patients with nonsmall-cell lung cancer (NSCLC) without epidermal growth factor
receptor (EGFR) mutations still respond to gefitinib and erlotinib, suggesting that there may …
receptor (EGFR) mutations still respond to gefitinib and erlotinib, suggesting that there may …
TD-19, an Erlotinib Derivative, Induces Epidermal Growth Factor Receptor Wild-Type Nonsmall-Cell Lung Cancer Apoptosis through CIP2A-Mediated Pathway
TT Chao, CY Wang, CC Lai, YL Chen… - J. Pharmacol. Exp …, 2014 - ntur.lib.ntu.edu.tw
Some patients with nonsmall-cell lung cancer (NSCLC) without epidermal growth factor
receptor (EGFR) mutations still respond to gefitinib and erlotinib, suggesting that there may …
receptor (EGFR) mutations still respond to gefitinib and erlotinib, suggesting that there may …
TD-19, an erlotinib derivative, induces epidermal growth factor receptor wild-type nonsmall-cell lung cancer apoptosis through CIP2A-mediated pathway
TT Chao, CY Wang, CC Lai, YL Chen… - Journal of …, 2014 - scholar.nycu.edu.tw
Some patients with nonsmall-cell lung cancer (NSCLC) without epidermal growth factor
receptor (EGFR) mutations still respond to gefitinib and erlotinib, suggesting that there may …
receptor (EGFR) mutations still respond to gefitinib and erlotinib, suggesting that there may …
TD-19, an erlotinib derivative, induces epidermal growth factor receptor wild-type nonsmall-cell lung cancer apoptosis through CIP2A-mediated pathway.
TT Chao, CY Wang, CC Lai, YL Chen… - The Journal of …, 2014 - europepmc.org
Some patients with nonsmall-cell lung cancer (NSCLC) without epidermal growth factor
receptor (EGFR) mutations still respond to gefitinib and erlotinib, suggesting that there may …
receptor (EGFR) mutations still respond to gefitinib and erlotinib, suggesting that there may …
TD-19, an erlotinib derivative, induces epidermal growth factor receptor wild-type nonsmall-cell lung cancer apoptosis through CIP2A-mediated pathway
TT Chao, CY Wang, CC Lai… - The Journal of …, 2014 - pubmed.ncbi.nlm.nih.gov
Some patients with nonsmall-cell lung cancer (NSCLC) without epidermal growth factor
receptor (EGFR) mutations still respond to gefitinib and erlotinib, suggesting that there may …
receptor (EGFR) mutations still respond to gefitinib and erlotinib, suggesting that there may …
[PDF][PDF] TD-19, an Erlotinib Derivative, Induces Epidermal Growth Factor Receptor Wild-Type Nonsmall-Cell Lung Cancer Apoptosis through CIP2A-Mediated Pathway …
TT Chao, CY Wang, CC Lai, YL Chen… - THE JOURNAL OF …, 2014 - academia.edu
Some patients with nonsmall-cell lung cancer (NSCLC) without epidermal growth factor
receptor (EGFR) mutations still respond to gefitinib and erlotinib, suggesting that there may …
receptor (EGFR) mutations still respond to gefitinib and erlotinib, suggesting that there may …